Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00651937 · ClinicalTrials.gov registry record · Phase 2
Trial of Two Stem Cell Doses To Reduce Transplant Induced Symptom Burden
A Phase 2 study, sponsored by M.D. Anderson Cancer Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 80
- Enrollment target
NCT00651937: Completed Phase 2 study, sponsored by M.D. Anderson Cancer Center.
NCT00651937 is a Phase 2 study that has completed, run by M.D. Anderson Cancer Center. The registered enrollment target is 80 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00651937, a Phase 2 study, has completed, sponsored by M.D. Anderson Cancer Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 80 participants
- Enrollment target
Study Summary
The goal of this clinical research study is to learn whether higher doses of stem cells can help to decrease the symptoms that occur after melphalan. Another goal of the study is to see how the dose of infused stem cells affects the levels of certain proteins in your blood. Researchers also want to learn how the dose of stem cells that you receive affects the quality of your life during the weeks after the transplant procedure.
Interventions
- DRUG Melphalan
- BEHAVIORAL Questionnaires
- PROCEDURE Apheresis
- PROCEDURE Stem Cell Infusion
- DRUG Granulocyte-colony stimulating factor (G-CSF)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 80 participants |
| Start Date | 2008-03 |
| Est. Completion | 2016-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00651937
The ClinicalTrials.gov registry entry for NCT00651937 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 80 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Melphalan is the first listed.
NCT00651937 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00651937 about?
NCT00651937 is a clinical study titled "Trial of Two Stem Cell Doses To Reduce Transplant Induced Symptom Burden". The goal of this clinical research study is to learn whether higher doses of stem cells can help to decrease the symptoms that occur after melphalan. Another goal of the study is to see how the dose of infused stem cells affects the levels of certain proteins in your blood. Researchers also want to ...
What is the current status of trial NCT00651937?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 80 participants. The study started on 2008-03. Estimated completion is 2016-01.
What interventions are being tested in trial NCT00651937?
The interventions under investigation include: Melphalan (DRUG), Questionnaires (BEHAVIORAL), Apheresis (PROCEDURE), Stem Cell Infusion (PROCEDURE), Granulocyte-colony stimulating factor (G-CSF) (DRUG).
Who is sponsoring clinical trial NCT00651937?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.